Overview

Neuropathic Pain Management Market Dynamics:

Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain. Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market.

Neuropathic Pain Management Market Segmentation:

By Drug Class
•   Tricyclic Antidepressants
•   Anticonvulsants
•   SNRIs
•   Capsaicin Cream
•   Local Anaesthesia
•   Opioids
•   Steroids
•   Others
By Indication
•   Diabetic Neuropathy
•   Trigeminal Neuralgia
•   Post-Herpetic Neuralgia
•   Chemotherapy-Induced Peripheral Neurotherapy
•   Others
By Distribution Channel
•   Retail Pharmacies
•   Hospital Pharmacies
•   Online Pharmacies
By Region
•   North America
•   Europe
•   Asia Pacific
•   Latin America
•   Middle East & Africa

The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations.

Regional Analysis:

The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region.

Competitive Landscape:

The major players included are Pfizer Inc., Johnson & Johnson Services Inc., Depomed Inc., Bristol-Myers Squibb and Company, Sanofi S.A., Biogen Idec Inc., Eli Lily and Company, GlaxoSmithKline PLC, Baxter Healthcare Corporation.

FutureWise Key Takeaways:

•   Growth prospects
•   SWOT analysis
•   Key market trends
•   Key data-points affecting market growth

Objectives of the Study:

•   To provide with an exhaustive analysis on the global neuropathic pain management market by drug class, by indication, by distribution channel and by region
•   To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•   To evaluate and forecast micro-markets and the overall market
•   To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•   To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com